Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Scheltens

Showing results (431-440 of 903) with videos related to

Pageof 91
Sort By:
Cerebrovascular Diseases (Basel, Switzerland)|January 27, 2012
2001-2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease?, Anna Poggesi, Leonardo Pantoni, et al.
Neurology|January 25, 2022
Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy BodiesMarleen van de Beek, Floor A H Ooms, Jarith L Ebenau, et al.
The Journal of Clinical Psychiatry|September 7, 2010
White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patientsMardien L Oudega, Eric van Exel, Mike P Wattjes, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 8, 2022
Quantification of [<sup>18</sup> F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE projectLyduine E Collij, Gemma Salvadó, Arno de Wilde, et al.
Neurobiology of Aging|July 15, 2014
Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's diseaseMarije R Benedictus, Maja A A Binnewijzend, Joost P A Kuijer, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 22, 2018
A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibilityRoos J Jutten, John Harrison, Philippe R Lee Meeuw Kjoe, et al.
Alzheimer'S Research & Therapy|January 5, 2021
Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohortsFlora H Duits, Kirsten E J Wesenhagen, Laura Ekblad, et al.
The Lancet. Healthy Longevity|September 13, 2022
Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort studyInge M W Verberk, Malika B Laarhuis, Karlijn A van den Bosch, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|May 17, 2012
No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleedsDaniëlle M E van Assema, Jeroen D C Goos, Wiesje M van der Flier, et al.
JAMA Neurology|September 15, 2015
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer DiseaseMaartje I Kester, Charlotte E Teunissen, Daniel L Crimmins, et al.
Pageof 91

Showing results (431-440 of 903) with videos related to

Sort By:
Pageof 91
Cerebrovascular Diseases (Basel, Switzerland)|January 27, 2012
2001-2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease?, Anna Poggesi, Leonardo Pantoni, et al.
Neurology|January 25, 2022
Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy BodiesMarleen van de Beek, Floor A H Ooms, Jarith L Ebenau, et al.
The Journal of Clinical Psychiatry|September 7, 2010
White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patientsMardien L Oudega, Eric van Exel, Mike P Wattjes, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 8, 2022
Quantification of [<sup>18</sup> F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE projectLyduine E Collij, Gemma Salvadó, Arno de Wilde, et al.
Neurobiology of Aging|July 15, 2014
Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's diseaseMarije R Benedictus, Maja A A Binnewijzend, Joost P A Kuijer, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 22, 2018
A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibilityRoos J Jutten, John Harrison, Philippe R Lee Meeuw Kjoe, et al.
Alzheimer'S Research & Therapy|January 5, 2021
Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohortsFlora H Duits, Kirsten E J Wesenhagen, Laura Ekblad, et al.
The Lancet. Healthy Longevity|September 13, 2022
Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort studyInge M W Verberk, Malika B Laarhuis, Karlijn A van den Bosch, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|May 17, 2012
No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleedsDaniëlle M E van Assema, Jeroen D C Goos, Wiesje M van der Flier, et al.
JAMA Neurology|September 15, 2015
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer DiseaseMaartje I Kester, Charlotte E Teunissen, Daniel L Crimmins, et al.
Pageof 91